Journavx, the new non-addictive FDA approved pain management medication -

Journavx, the new non-addictive FDA approved pain management medication

Journavx, the new non-addictive FDA approved pain management medication. (www.fda.gov) The U.S. Food and Drug Administration has granted approval to Journavx, 50-milligram oral tablet designed to alleviate moderate to severe acute pain in adults. This is a non-opioid pain medication that operates by disrupting the pain-signaling pathway linked to sodium channels in the nervous system,…

January 31, 2025

1–2 minutes

Discover more from Midwest Link Journal

^{MLJ. Voice for non legacy media. SUBSCRIBE TO MLJ For Unlimited Content}

_{^{Join our newsletter}}

Journavx, the new non-addictive FDA approved pain management medication

Journavx, the new non-addictive FDA approved pain management medication.

(www.fda.gov) The U.S. Food and Drug Administration has granted approval to Journavx, 50-milligram oral tablet designed to alleviate moderate to severe acute pain in adults. This is a non-opioid pain medication that operates by disrupting the pain-signaling pathway linked to sodium channels in the nervous system, preventing pain signals from reaching the brain.

As a non-addictive alternative for managing acute pain, Journavx holds the promise to transform current methodologies in pain relief and set a new standard in care, according to Vertex CEO Reshma Kewalramani, M.D.

Notably, Journavx is the inaugural medication in this novel category of pain management treatments. Vertex has set the price at $15.50 for a single 50-mg dosage, totaling $420 for a two-week treatment regimen.(fiercepharma.com)

Pain remains a prevalent medical issue, making effective pain relief a critical objective in therapy. Acute pain typically arises from tissue damage due to trauma or surgical procedures and is frequently managed with various analgesics that may include opioids or alternative options.

The FDA has consistently backed the advancement of non-opioid pain relief solutions.

Through its Overdose Prevention Framework, the agency has released draft guidelines to promote the development of non-opioid analgesics for acute pain and has provided grants to facilitate the creation and distribution of clinical practice guidelines pertinent to managing acute pain conditions.

Jacqueline Corrigan-Curay, J.D., M.D., acting director of the FDA’s Center for Drug Evaluation and Research, remarked that today’s approval marks a milestone for public health in the realm of acute pain management, introducing a new class of non-opioid analgesics.

According to research participants, the most frequently reported side effects of Journavx included itching, muscle spasms, higher levels of creatine phosphokinase in the blood, and skin rashes. It is essential to avoid using Journavx alongside strong CYP3A inhibitors and to refrain from consuming grapefruit products during treatment.